



Assessment of Appropriate Treatment of *Staphylococcus aureus* Bacteremia

Essie Samuel, PharmD, BCPS, Tanea Womack, PharmD, MBA, BCPS
Philadelphia College of Osteopathic Medicine – Georgia Campus, School of Pharmacy, Suwanee, GA
Wellstar North Fulton Hospital, Roswell, GA



BACKGROUND

- *Staphylococcus aureus* bacteremia (SAB) increases rates of morbidity and mortality and requires rapid and appropriate antimicrobial selection to resolve symptoms and remove the infection
- Treatment of choice is a β -lactam or vancomycin for MSSA and MRSA bacteremia, respectively
- Uncomplicated SAB:
 - Short-course treatment with systemic antibiotics for 14 days
 - Long-course treatment for 28 days is preferred to eliminate potential for complications and relapse
- Complicated SAB:
 - Long-course treatment is recommended at ≥ 4 weeks

OBJECTIVE

- To assess appropriate treatment of SAB (by antibiotic selection and duration of therapy) and to determine if targeted therapy, relapse or SAB-related readmission, length of stay, and mortality rates were affected by the presence of an Infectious Disease (ID) consultation
 - Primary Outcome
 - Percentage of patients treated appropriately for SAB (by antibiotic selection and duration of therapy)
 - Secondary Outcomes
 - Antimicrobial stewardship interventions
 - Timing of ID consults
 - Difference in outcomes due to presence of an ID consult
 - Appropriate targeted therapy
 - Recurrence or SAB-related readmission, length of stay, and mortality rate

METHODS

- A retrospective chart review was conducted by Wellstar hospital system in the greater Atlanta area from January 1 to June 30 in 2017
- Patients were identified from microbiology reports of positive blood cultures with *S.aureus*
- Information collected includes baseline characteristics, selection and duration of antibiotic therapy, presence of ID consultations, and follow up reports of complications post therapy
- Patient Population
 - Inclusion criteria
 - ≥ 18 yrs of age
 - *S. aureus* isolated from one or more blood cultures
 - Exclusion criteria
 - Antibiotic susceptibilities unavailable prior to death
 - Care withdrawn prior to therapy being selected or targeted therapy completed
- Statistical analysis: descriptive analysis


RESULTS

- Eight patients at Wellstar North Fulton hospital presented with *S. aureus* bacteremia during January, 2017 to June, 2017
- One patient was excluded as care was withdrawn prior to the completion of targeted therapy


Primary Outcome:

- Percentage of patients treated appropriately for SAB based on:
 - Antibiotic selection: 7 out of 7 patients
 - Duration of therapy: 5 out of 7 patients

Primary Outcome: Appropriate Selection of Antibiotics and Duration




Primary Outcome: Appropriate Selection of Antibiotics Alone



Secondary Outcomes:

- Antimicrobial Stewardship Interventions: 5 out of 7 patients had documented interventions that were accepted
- Timing of ID Consultations: 4 out of 7 patients had an ID consult placed on the first day. ID was consulted on days 2, 3, or 5 for the remaining patients

Secondary Outcomes



DISCUSSION

- Complete data collection and analysis at all Wellstar facilities pending
- At Wellstar North Fulton hospital, primary outcome of appropriate treatment of SAB based on appropriate antibiotic selection and appropriate duration of therapy was met in 71% (5 out of 7) patients
 - However, one patient expired prior to the completion of therapy. Primary outcome was met in 83% (5 out of 6) patients if excluding that patient.
 - One patient who qualified for long-course treatment received only a short course
- Vancomycin was the most common agent used for MRSA bacteremia. Alternatives included daptomycin, ceftaroline, and linezolid based on concurrent infections
- Vancomycin was started initially for the MSSA patients but later changed to ceftriaxone or nafcillin upon confirmation of MSSA. Some patients also received piperacillin/tazobactam or meropenem for MSSA for concurrent Gram-negative and anaerobic coverage
- Difference in outcomes due to the presence of ID consultation was difficult to assess in this small subset of patients.
 - Upon completion of data collection/assessment at all facilities, these outcomes will be evaluated

CONCLUSION

- *S.aureus* bacteremia was treated appropriately in majority of patients when reviewing selection of antibiotics and duration of treatment. Practitioners will be educated to re-emphasize longer treatment durations for patients with diabetes, evidence of immunosuppression, metastatic infection, endocarditis, prosthetic or intravascular devices, and lack of improvement within 72 hours of antibiotic treatment.

REFERENCES

- Paulsen J, Solligard E, et al. The Impact of Infectious Disease Specialist Consultation for Staphylococcus aureus Bloodstream Infections: A Systematic Review. *Open Forum Infect Dis* 2015; 22 Sept:1-10
- Corey GR, Stryjewski ME, Everts RJ. Short-course therapy for bloodstream infections in immunocompetent adults. *Int J Antimicrob Ag* 2009;34S:S47-S51.
- Corona A, Wilson APR, et al. Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of shortcourse monotherapy. *J Antimicrob Chemotherapy* 2004;54:809-17.
- Abraham J, Mansour C, et al. Staphylococcus aureus bacteremia and endocarditis: The Grady Memorial Hospital Experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. *Am heart J* 2004;147:536-9.
- Bamberger DM and Boyd SE. Management of Staphylococcus aureus Infections. *Am Fam Physician* 2005;72:2474-81.
- Mermel LA, Allon M, et al. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-related Infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009;49:1-45.
- Fowler VG, Sanders LL, et al. Outcome of Staphylococcus aureus Bacteremia According to Compliance with Recommendations of Infectious Diseases Specialists: Experience with 244 patients. *Clin Infect Dis* 1998;27:478-86.
- Johnson LB, Almoujahed MO, et al. Staphylococcus aureus Bacteremia: Compliance with Standard Treatment, Long-term Outcome and Predictors of Relapse. *Scand J Infect Dis* 2003;35:782-89.
- Petti CA and Fowler VG. Staphylococcus aureus bacteremia and endocarditis. *Infect Dis Clin N Am* 2002;16:413-35.
- Ehni WF and Reller LB. Short-Course Therapy for Catheter-Associated Staphylococcus aureus Bacteremia. *Arch Intern Med* 1989;149:533-36.
- Wenzler E, Wang F, et al. An Automated, Pharmacist-Driven Initiative Improves Quality of Care for Staphylococcus aureus Bacteremia. *Clin Infect Dis* 2017;65(2):194-200.
- Turner, RB, Valcarlos E, et al. Impact of Infectious Disease Consultation on Clinical Outcomes of Patients with Staphylococcus aureus Bacteremia in a Community Health System. *Antimicrob Agents Chemother* 2016;60(10):5682-5687.
- Pragman AA, Kuskowski MA, et al. Infectious Disease Consultation for Staphylococcus aureus Bacteremia Improves Patient Management and Outcomes. *Infect Dis Clin Pract* 2012;20(4):261-267.

DISCLOSURES

Authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation